|
Dr. Rowinsky has served as a director since February 2008. Dr. Rowinsky currently serves as Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated. Prior to joining ImClone Systems in 2005 Dr. Rowinsky focused his academic efforts in cancer drug development as the Director of Clinical Research and later Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio and the SBC Endowed Chair for Early Drug Development from 1996 to 2005. He was also Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio from 1996 to 2006. From 1987 to 1996 Dr. Rowinsky served as an Associate Professor of Oncology at the Johns Hopkins University School of Medicine. He was a longstanding NCI principal investigator on U01 anticancer drug development grants and integrally involved in pivotal clinical and preclinical investigations which led to the development of paclitaxel docetaxel topotecan irinotecan erlotinib and gefitinib among others.
Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs an Associate Editor and/or Editorial Board Member of Cancer Research (Associate Editor and Reviews Editor) Clinical Cancer Research Annals of Oncology Cancer Biology and Therapy and several other oncology journals and has published over 270 manuscripts in both the preclinical and clinical research fields. He has also served on the Scientific Advisory Board and Project Advisory Boards of a large number of pharmaceutical and biotechnology companies and has advised and/or presented aspects of New Drug Applications to the FDA on several occasions. Dr. Rowinsky's honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. He also served on the Board of Scientific Counselors of the National Cancer Institute.
Dr. Rowinsky received his B.A. degree from New York University and his M.D. from the Vanderbilt University School of Medicine. Following his residency in internal medicine at the University of California he completed fellowship training in medical oncology at the Johns Hopkins University School of Medicine | 